Pharma BD Deal Intelligence
A licensing/collaboration expansion, not an acquisition: Roche paid Halozyme $30M upfront (plus milestones/royalties) for ENHANZE rights on an undisclosed target, building on their 2006 tie-up. It paid off—ENHANZE underpinned Phesgo, a genuine Roche growth driver, while Halozyme remained independent and thrived as a royalty-licensing platform.
Not an acquisition: Roche never bought Halozyme (still independent, NASDAQ: HALO); this was an ENHANZE tech-licensing deal that successfully delivered Phesgo, a genuine Roche growth driver
Full analysis, sources & comparables →Form 8-K exhibit documents the expanded ENHANZE collaboration and license agreement with Roche, including the new target license, upfront payment, milestone…
Halozyme inks $2B+ in ENHANZE licensing deals with BMS and Roche; Roche's extension underscores growing demand for subcutaneous reformulation of biologics.
ENHANZE is now used in 10+ commercial co-administered products in 100+ countries with tens of billions of dollars in commercial revenue across Roche, J&J,…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Roche expanded its longstanding ENHANZE collaboration with Halozyme to add an additional undisclosed therapeutic target. Halozyme received $30M upfront plus eligibility for up to $160M in development, regulatory and sales-based milestones plus tiered royalties. The expansion built on the original 2006 collaboration that produced subcutaneous Herceptin and MabThera/Rituxan formulations.
Not an acquisition: Roche never bought Halozyme (still independent, NASDAQ: HALO); this was an ENHANZE tech-licensing deal that successfully delivered Phesgo, a genuine Roche growth driver
Assessment window: 10yr post-close.
ENHANZE is a drug-delivery platform, not a disease therapy: recombinant human hyaluronidase PH20 (rHuPH20) temporarily depolymerizes hyaluronan in subcutaneous tissue to allow large-volume biologic injection that would otherwise require IV infusion. The clinical value proposition is shorter administration time, shift from infusion suite to office or home, and improved patient quality of life — a meaningful franchise-extension lever for blockbuster IV biologics facing biosimilar pressure.
ENHANZE is the dominant subcutaneous-conversion platform for biologics, with the Roche relationship dating to 2006 and producing Herceptin SC, MabThera/Rituxan Hycela, and Phesgo (pertuzumab+trastuzumab fixed-dose). Competing approaches include Antares Pharma's QuickShot/Vibex auto-injectors, Eitan Medical/Sorrel patch pumps, and proprietary high-concentration formulation chemistry, but no competing enzymatic permeation enhancer has reached comparable scale. The September 2017 expansion was modest in headline value ($30M upfront, up to $160M milestones plus tiered royalties) but strategically meaningful: it added another Roche target on top of the existing collaboration just months after Bristol-Myers Squibb signed a much larger ENHANZE deal ($105M upfront, up to 11 targets, $1.9B milestone potential per BioPharma Dive 2017). Combined, the 2017 deals doubled Halozyme's revenue guidance to $245-260M and signaled platform validation by IO leaders. Subsequent ENHANZE deals followed with Janssen, argenx, Alexion, and others; Halozyme guided to $1B in annual ENHANZE royalties by 2027 (Halozyme IR). The Roche expansion specifically positioned the partnership for subsequent Tecentriq Hybreza (atezolizumab SC, 2024 approval) and Ocrevus Zunovo (ocrelizumab SC, 2024 approval). [https://www.fiercebiotech.com/biotech/roche-taps-halozyme-s-drug-delivery-tech-for-up-to-520m]
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Halozyme Therapeutics, Inc. (this deal) | 2017 | $190M | 75 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2017 deals · Roche Holding AG deals · Multiple (undisclosed) deals